Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

ABCL - AbCellera Biologics Inc. Последние новости | Finranks

Home

ABCL

A

AbCellera Biologics Inc. (ABCL)

NMS – Цена в реальном времени. Валюта: USD

3.27

-0.08 (-2.39%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

3.26

-0.01 (-0.31%)

После закрытия: Mar 27, 2026, 7:34 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

AbCellera Biologics Inc. (ABCL) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript

AbCellera Biologics Inc. (ABCL) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript

AbCellera Biologics Inc. (ABCL) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript

AbCellera Biologics Inc. (ABCL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

AbCellera Biologics Inc. (ABCL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

AbCellera Biologics Inc. (ABCL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Tops Revenue Estimates

AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Tops Revenue Estimates

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.11 per share a year ago.

AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript

AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript

AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript

AbCellera Reports Full Year 2025 Business Results

AbCellera Reports Full Year 2025 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Full Year 2025 Business Results.

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at Upcoming Investor Conferences in March and April 2026.

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Full Year 2025 Financial Results on February 24, 2026.

Видео

No Data

There is no data to display

Пресс-релизы

AbCellera Reports Full Year 2025 Business Results

AbCellera Reports Full Year 2025 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Full Year 2025 Business Results.

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

12.01.2026

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of VMS Due to Menopause.

AbCellera and Bruker Reach Global Settlement of Patent Litigation

AbCellera and Bruker Reach Global Settlement of Patent Litigation

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera and Bruker Reach Global Settlement of Patent Litigation.

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Appoints Dr. Stephen Quake to its Board of Directors.